Keymed Biosciences, Inc. (HK:2162) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Keymed Biosciences Inc. has entered an exclusive license agreement with Platina Medicines Ltd, granting them rights to develop, manufacture, and commercialize the bispecific antibody CM336 outside China, Hong Kong, Macau, and Taiwan. The deal includes an upfront payment of $16 million to Keymed and potential milestone payments up to $610 million, along with royalties on sales. This agreement aims to expand Keymed’s global presence and maximize the commercial potential of its technology.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.